Roxithromycin
Roxid · Rulid · Roxithromycin (Roxl-150) · Roxithromycin Solution, 100ppm · Brilid · Overal · RU 965 · Surlid
Identifikatoren & physikalische Daten
| CAS No. | 80214-83-1 |
|---|---|
| Summenformel | C41H76N2O15 |
| Durchschnittliche Molmasse | 837 g/mol |
| Monoisotopische Masse | 836,52456972 g/mol |
| SMILES | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O |
| InChIKey | RXZBMPWDPOLZGW-XMRMVWPWSA-N |
| PubChem CID | 6915744 |
| ChEMBL | CHEMBL1214185 |
| ChEBI | CHEBI:48844 |
| EC No. | 617-007-5 |
Chemische & physikalische Eigenschaften
| XLogP | 3,1 |
|---|---|
| Polarare Oberfläche (TPSA) | 217 |
| H-Brücken-Donoren | 5 |
| H-Brücken-Akzeptoren | 17 |
| Frei drehbare Bindungen | 13 |
| Schwere Atome | 58 |
| Formalladung | 0 |
| Komplexität | 1.310 |
| Arzneimittel | Pharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 3.46 |
| Human Drugs | Breast FeedingLactationAnti-Bacterial AgentsAnti-Infective AgentsMacrolides |
| Dissociation Constants | 9.27 |
| Collision Cross Section | 285.66 Ų [M+Na]+ |
| Schmelzpunkt | 111-118C |
| Siedepunkt | 864.7±75.0 °C(Predicted) |
| Dichte | 1.25±0.1 g/cm3(Predicted) |
| Flammpunkt | >110°(230°F) |
| Lagerbedingungen | Sealed in dry,2-8°C |
| Löslichkeit | chloroform: soluble10mg/mLSoluble in water to 18µ |
| pKa (Säurekonstante) | pKa 9.27±0.01(H2O t = 25.0 I = 0.15 (KCl)) (Uncertain) |
| Aggregatzustand | powder |
| Farbe | White to off-white |
| Merck | 14,8276 |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChIKey | RXZBMPWDPOLZGW-HEWSMUCTSA-N |
| SMILES | CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC3OC(C)CC(C3O)N(C)C)C(C)(O)CC(C)C(=N/OCOCCOC)\C(C)C(O)C1(C)O |
| CAS Datenbank | 80214-83-1 |
| EPA chemische Informationen | Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime], (9E)- (80214-83-1) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 67 reports by companies from 2 notifications to the ECHA C&L Inventory.DangerH302: Harmful if swallowed [Warning Acute toxicity, oral] |
|---|---|
| Regulatorische Informationen | Roxithromycin: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Acute Tox. 4 (100%)Acute toxicity (Oral) - Category 4 |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)ROXITHROMYCINDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 29415000 |
| RTECS-Nr. | KF4990000 |
| R-Sätze (R) | 22 |
| Gefahrensymbole | Xn |
| Sicherheitshinweise (S) | 26-24/25 |
| Lagerklasse | 11 - Combustible Solids |
| Gefahrenklasse | Acute Tox. 4 Oral |
Anwendungen & Verwendung
Beschreibung
Roxithromycin, an oxime ether derivative of erythromycin, is a new macrolide antibiotic of high potency and long duration. Its in v i m activity spectrum is similar to that of erythromycin, but is superior to the latter against Legionella, Mycoplasma and Chlamydia.
Verwenden
Roxithromycin was one of the new generation erythromycins introduced in the 1980s. Improved acid stability was achieved by converting the 9-keto group to the more stable oxime and alkylation of the oxime to provide the methoxyethoxymethyl ether oxime. In vivo, roxithromycin exhibits higher tissue levels and a longer half-life while being slightly less potent than erythromycin in vitro.